New heart-safer drug combo tested for tough-to-treat blood cancer
NCT ID NCT07486726
Summary
This study is testing a new three-drug combination for adults with acute myeloid leukemia (AML), a serious blood cancer. It aims to find the safest and most effective dose of aclarubicin when added to two standard drugs, azacitidine and venetoclax. The goal is to better control the disease, especially for patients who are newly diagnosed but cannot tolerate strong chemotherapy or whose cancer has returned or resisted prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Jing'an District Beizhan Hospital
Shanghai, China
Contact Phone: •••-•••-••••
-
Shanghai Traditional Chinese Medicine Hospital
Shanghai, China
Contact Email: •••••@•••••
-
Tongren Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.